The GLP-1 Revolution: Semaglutide, Obesity & India’s Pharma Race | PCG2025

GLP-1 is no longer just a weight-loss story. It’s becoming one of pharma’s biggest opportunities Bringing together perspectives from Novo Nordisk, Eli Lilly, Biocon, Dr. Reddy’s Laboratories and Levim Lifetech, plenary panel from PCG2025 brought together leaders from across the GLP-1 ecosystem to unpack the rapid rise of these therapies. Meet the Panel Mr. Vikrant Shrotriya, Corporate Vice President and Managing Director, Novo Nordisk Bringing the perspective of a global leader at the forefront of GLP-1 therapies and the rapidly evolving obesity care landscape. Mr. Siddharth Mittal, CEO & MD, Biocon Ltd. Sharing an industry perspective on biologics, biosimilars and India’s opportunity in the expanding GLP-1 market. Mr. Winselow Tucker, President & General Manager, Eli Lilly & Co. (India) Pvt. Ltd. Offering insights from another major player shaping the next generation of metabolic and obesity therapies. Dr. Subramanian Narayanaswamy, Head of Delivery, Parenteral Injectables – IPDO, Dr. Reddy’s Laboratories Bringing expertise from the pharmaceutical development and injectable manufacturing ecosystem. Mr. Jatin Vimal, Director, Levim Lifetech Pvt. Ltd. Adding the perspective of an emerging player working across the evolving peptide and GLP-1 landscape. Moderated by Mr. Vikas Dandekar, the discussion brings together diverse industry perspectives on one of pharma’s most closely watched therapeutic areas. Connect with us: Website: https://pcgsymposium.com/ Linkedin:   / peptides-complex-generics-symposium   Subscribe and Stay tuned for More! Disclaimer: The views expressed are those of the speaker and do not necessarily reflect those of the organizers. This content is for informational and professional purposes only. #GLP1 #Semaglutide #GLP1Drugs #Obesity #Peptides #Biosimilars #Biopharma #Pharma #PCG2025 #IndianPharma